A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Terminated
Incyte Corporation
Phase 1/Phase 2
The study design includes an open-label, dose escalation phase followed by a blinded,
randomized phase, which combines epacadostat (an oral IDO1 inhibitor) with an approved
therapy and compares to approved therapy plus placebo in metastatic melanoma patients.
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
Terminated
Incyte Corporation
Phase 2
This is an open-label, randomized, phase 2 study of an IDO inhibitor, INCB024360
(epacadostat) versus tamoxifen in biochemical recurrent only ovarian cancer patients
following complete remission with first-line chemotherapy.
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Completed
Incyte Corporation
Phase 2
This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating
patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens
may help the body build an effective immune response to kill tumor cells. Giving epacadostat
with vaccine therapy may be an effective treatment for advanced melanoma.
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Completed
National Cancer Institute (NCI)
Phase 2
This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating
patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens
may help the body build an effective immune response to kill tumor cells. Giving epacadostat
with vaccine therapy may be an effective treatment for advanced melanoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.